Resveratrol is a polyphenol with major health benefits 1 This finding suggests that resveratrol may promote SIRT1 function by enhancing NAD + synthesis in whole cell systems without requiring direct activation.
Resveratrol is a non-vitamin antioxidant common in the diet and particularly abundant in teas, juices, and red wines that is thought to harbour major health benefits 1 . Experiments in single and multicellular organisms and human tissue cultures suggest that resveratrol can extend the lifespan in diverse organisms by activating the NAD + dependent, enzyme, SIRT1 7 .
The neuroprotective ability of SIRT1 induced by resveratrol has been demonstrated in vitro 6 .
While resveratrol has been claimed to be a direct SIRT1 activator using the Fluor de Lys-SIRT1 peptide substrate, recent reports indicate that this finding may represent an experimental artefact [3] [4] . Our study indicates resveratrol directly activates the enzyme NMNAT1 which likely influences downstream SIRT1 activity.
We demonstrate for the first time that resveratrol significantly increases intracellular NAD + levels in primary human astrocytes and neurons (Fig 1) . We have shown that resveratrol can induce a dose dependent increase in NAD + of 3-5 fold in human astrocytes ( Fig 1A) and neurons ( Fig 1B) after 24-hour treatment. It has been known for some time that resveratrol can influence NAD + responsive enzymes, such as the energy-sensing AMPactivated kinase (AMPK) 8 and SIRT2 2 and its mammalian homologue, SIRT1 2, 9 . However to date no study has reported a link between resveratrol and changes in NAD + concentration.
Elevated cellular levels of NAD + , the required substrate for SIRT1, will increase its activity.
Nicotinamide mononucleotide adenylyltransferase (NMNAT) is an NAD + synthetic enzyme which catalyses the conversion of nicotinamide mononucleotide (NMN) to NAD + .
NMNAT1 is the predominant human isoform of NMNAT and is located in the nucleus 6 .
Increased NMNAT1 expression has been reported to protect against axonal degradation via increased NAD + production in mouse neurons 6 . In the same study, neurons treated with resveratrol prior to axotomy showed a decrease in axonal degeneration that was comparable to that obtained with NAD + 6 . It has also been previously demonstrated that increased SIRT1 deacetylase activity can protect against axonal degradation in models of AD, although the exact mechanism is still unknown 10 . As NAD + is an essential substrate for SIRT1, the effect of resveratrol on SIRT1 proteins may be due, at least in part, to an NMNAT mediated increase in NAD + .
We tested the effect of resveratrol on NMNAT activity in cell homogenates of human foetal astrocytes and human recombinant-NMNAT1. We found that resveratrol (200 µM) increased NMNAT1 activity in crude astrocytic homogenates by 70% within 24 hours (Fig 1C) . Using human recombinant NMNAT1, we observed that resveratrol lowered the K m for the substrate NMN by up to 3-fold, and increased V max for the recombinant NMNAT1 by up to 5 fold in a dose dependent manner (Table 1) . Our results are consistent with resveratrol acting as a heterotropic allosteric modulator of NMNAT1 at an as yet unidentified site. Further work is required to characterise this novel resveratrol-NMNAT1 interaction.
Our observation that resveratrol increases NAD + levels in primary human brain cells by acting on NMNAT supports the view that this polyphenol has considerable therapeutic potential; particularly for the treatment of neurodegenerative diseases. As NMNAT can accelerate NAD + synthesis from all three substrates, quinolinic acid, nicotinic acid and nicotinamide 11 , NMNAT activation by resveratrol represents an ideal natural therapeutic to replenish NAD + levels. Maintenance of higher cellular NAD + will enhance SIRT1 activity, and other NAD + dependent pathways impacting positively on cell viability and longevity.
This work has therefore formed the basis of relevant patent applications. 
